E-Book, Englisch, Band Volume 103, 160 Seiten
Reihe: Advances in Cancer Research
Vande Woude / Klein Advances in Cancer Research
1. Auflage 2009
ISBN: 978-0-08-091226-4
Verlag: Elsevier Science & Techn.
Format: EPUB
Kopierschutz: 6 - ePub Watermark
E-Book, Englisch, Band Volume 103, 160 Seiten
Reihe: Advances in Cancer Research
ISBN: 978-0-08-091226-4
Verlag: Elsevier Science & Techn.
Format: EPUB
Kopierschutz: 6 - ePub Watermark
Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics, including nitric oxide-induced apoptosis in tumor cells, detection of minimal residual disease, immunity to oncogenetic human papillomavirus, and modeling prostate cancer in the mouse.
Autoren/Hrsg.
Weitere Infos & Material
1;Front Cover;1
2;Advances in Cancer Research;4
3;Copyright;5
4;Contents;6
5;Contributors;8
6;Chapter 1: The Function, Proteolytic Processing, and Histopathology of Met in Cancer;10
6.1;I. Introduction;11
6.2;II. Oncogenic Properties of Met;12
6.3;III. Receptor Cross Talk;12
6.4;IV. Proteolytic Processing of Met;14
6.5;V. Nuclear Localization of Met;17
6.6;VI. Histopathology and Expression of Met in Cancer;18
6.7;VII. Met as a Therapeutic Target;23
6.8;VIII. Perspective;24
6.9;References;25
7;Chapter 2: Managing Tumor Angiogenesis: Lessons from VEGF-Resistant Tumors and Wounds;34
7.1;I. Angiogenesis;35
7.2;II. Vegf and Tumor Angiogenesis;36
7.3;III. Vegf and Recruitment of Epc in Tumor Angiogenesis;36
7.4;IV. Role of Bone Marrow-Derived Immune Cells in Angiogenesis and Tumor Progression;37
7.5;V. Limitations in Targeting Vegf;38
7.6;VI. Tumor Stage-Dependent Responses TVegf;39
7.7;VII. Multiple Angiogenic Factors Produced by the Tumor Microenvironment;40
7.8;VIII. Vegf Inhibition and Increased Tumor Aggressiveness;41
7.9;IX. Wound Angiogenesis;42
7.10;X. Vascular Regression;44
7.11;XI. Wound Fibroblasts;45
7.12;XII. Hox Genes in Wound and Tumor Angiogenesis;46
7.13;References;47
8;Chapter 3: The TRAIL to Targeted Therapy of Breast Cancer;52
8.1;I. Introduction;52
8.2;II. TRAIL and Its Receptors;54
8.3;III. TRAIL-Induced Apoptosis in Breast Cancer Cells;60
8.4;IV. Mechanisms Determining TRAIL Sensitivity in Breast Cancer Cells;64
8.5;V. Overcoming TRAIL Resistance;67
8.6;VI. Future Directions;73
8.7;Acknowledgments;73
8.8;References;73
9;Chapter 4: Hepatitis B Virus X Protein: Molecular Functions and Its Role in Virus Life Cycle and Pathogenesis;84
9.1;I. Introduction;84
9.2;II. Is HBx an Essential or Accessory Regulatory Protein for Virus Replication?;86
9.3;III. HBx: A Potential Candidate in HCC Development;88
9.4;IV. HBx: Structural and Biochemical Features;89
9.5;V. HBx Activities;92
9.6;VI. Conclusion;103
9.7;References;104
10;Chapter 5: Drosophila Myc;120
10.1;I. Introduction: The Myc/Max/Mxd network in vertebrates;120
10.2;II. The Myc/Max/Mnt network in flies;122
10.3;Acknowledgments;147
10.4;References;147
11;Index;154
12;Color Plate;158
Chapter 1 The Function, Proteolytic Processing, and Histopathology of Met in Cancer
Jason A. Hanna, Jennifer Bordeaux, David L. Rimm and Seema Agarwal
I. Introduction
II. Oncogenic Properties of Met
III. Receptor Cross Talk
Fig. 1 Met cross talk with other membrane receptors. Met interacts with the cell adhesion receptors E-cadherin, CD44v6, ?6?4 integrin, members of the Plexin B family, the death receptor Fas, and other receptor tyrosine kinases such as Ron and ErbB family members. |